Long-term Follow-up in 1,528 Left Main PCI Patients from a Large Single Center Experience

Xu Bo

Fu Wai Hospital, National Center for Cardiovascular Diseases, China



Background

- PCI with DES implantation has been considered an alternative therapy to CABG for left main (LM) patients with low to moderate risk according to previous randomized trials and registries
- We prospectively collected the PCI data and longterm clinical follow-up results (up to 8 years) in 1,528 consecutive patients undergoing LM PCI from Jan. 2004 to Dec. 2010 at Fu Wai Hospital



Wijns. W., et al. <u>Eur Heart J</u>. 2010 Kushner. FG., et al. <u>J Am Coll Cardiol</u>. 2009 Serruys, PW., et al. N <u>Engl J Med</u>. 2009 Mohr, FW., et al. <u>Lancet</u>. 2013

Proportion of LM Patients at Fu Wai



CAG: Patients undergoing coronary angiography only

CAG-LM: LM patients in CAG population

PCI: Patients undergoing percutaneous coronary intervention

PCI-LM: LM patients in PCI population

China In

Baseline Characteristics



	Results		
Age (years)	59.98±10.67		
Female	324 (21.2%)		
Prior MI	387 (25.3%)		
Prior PCI	343 (22.4%)		
Diabetes	369 (24.1%)		
Hypertension	824 (53.9%)		
Hyperlipidemia	766 (50.1%)		
Family History of CAD	183 (12.0%)		
Prior Stroke	100 (6.5%)		
Peripheral Vascular Disease	80 (5.2%)		
COPD	12 (0.8%)		
Current Smoker	433 (28.3%)		
LVEF (%)	62.81±7.55		
Angina			
Stable	464 (30.4%)		
Unstable	1017 (66.6%)		
Silent Ischemia	47 (3.1%)		
All data represented as n (%) or mean \pm SD			

Angiographic Characteristics &Different Scores

	Results
PCIAccess	
Radial Approach	861 (56.3%)
Femoral Approach	667 (43.7%)
LM Lesion Type	
De Novo	1482 (97.0%)
Restenotic	46 (3.0%)
Number of Target Lesions	1.69±0.80
Number of Stents per Patient	2.16±1.15
IVUS Usage	575 (37.6%)
Complications During Procedure	61 (4.0%)
PCI Procedural Success	1507 (98.6%)
Baseline SYNTAX Score	23.95 ± 7.06
Residual SYNTAX Score	4.42 ± 5.87
Modified ACEF Score	1.21 ± 0.75
Clinical SYNTAX Score	29.74 ± 22.16
Logistic Clinical SYNTAX Score	8.34 ± 3.00
SYNTAX Score II – PCI	25.60 ± 7.83
SYNTAX Score II – CABG	26.72 ± 9.62
* All data represented as n (%) or mean +	- SD



Clinical Outcomes at 30 Days



China Interventional Therapeutics in Partnership with TCT

Long-Term Clinical Outcomes (Mean Follow-up of 4.4 Years)



Subgroup
DM vs. Non-DM



Background

- Scant data exist regarding the impact of diabetes mellitus status on PCI for LM coronary artery disease.
- We sought to compare the impact of the presence of DM at baseline among patients undergoing LM PCI on long-term ischemic outcomes.



Baseline Characteristics

	Diabetics N=369	Non-Diabetics N=1,159	Р
Age (years)	60.8 ± 9.7	59.7±11.0	0.059
Female	80 (21.7%)	244 (21.1%)	0.8
LVEF (%)	62.63±7.60	62.87±7.54	0.59
Prior MI	110 (29.8%)	277 (23.9%)	0.02
Prior PCI	90 (24.4%)	253 (21.8%)	0.31
Hypertension	263 (71.3%)	561 (48.4%)	<0.0001
Hyperlipidemia	236 (64.0%)	530 (45.7%)	<0.0001
Prior Stroke	38 (10.3%)	62 (5.3%)	0.001
Peripheral Vascular Disease	23 (6.2%)	57 (4.9%)	0.33
COPD	5 (1.4%)	7 (0.6%)	0.18
Unstable Angina	236 (64.0%)	781 (67.4%)	0.31

Note: Data represented as n (%) or mean \pm SD

Angiographic Characteristics & Procedural Outcomes

	Diabetics N=369	Non-Diabetics N=1,159	Р
Angiographic Findings			0.0006
Isolated LM	21 (5.7%)	89 (7.7%)	
LM + 1VD	53 (14.4%)	261 (22.5%)	
LM + 2VD	139 (37.7%)	421 (36.3%)	
LM + 3VD	156 (42.3%)	388 (33.5%)	
LM Lesion Location			0.42
Ostium	49 (13.3%)	126 (10.9%)	
Shaft	22 (6.0%)	78 (6.7%)	
Distal Bifurcation	298 (80.8%)	955 (82.4%)	
Number of Target Lesions	1.80±0.87	1.66 ± 0.77	0.006
Number of Stents per Patient	2.31±1.23	2.11±1.12	0.006
PCI Procedural Success	367 (99.5%)	1140 (98.4%)	0.08
DAPT > 1 year	355 (96.2%)	1101 (95.0%)	0.33
Follow-up Duration (days)	1678±720	1564±739	0.009
Baseline SYNTAX Score	25.05 ± 7.19	23.59 ± 6.98	0.0005
Residual SYNTAX Score	5.09±6.11	4.20±5.78	0.01
Clinical SYNTAX Score	30.30±20.33	29.56±22.76	0.56
Logistic Clinical SYNTAX Score	8.55±2.76	8.27±3.07	0.10
SYNTAX Score II - PCI	26.08 ±7.78	25.44 ±7.84	0.17
SYNTAX Score II - CABG	27.38 ±8.77	26.51 ±9.87	0.11

Cox Regression Results without and with Multivariate Adjustment in Diabetics vs. Non-Diabetics

Variables	β Value	Р	Hazard Ratio [95%CI]
All Cause Death*	0.1693	0.5024	1.184 [0.722,1.943]
All Cause Death* *	0.2683	0.3262	1.308 [0.765,2.234]
Cardiac Death*	-0.0828	0.8102	0.921 [0.468,1.809]
Cardiac Death* *	-0.0466	0.9025	0.955 [0.453,2.010]
Stroke*	1.2442	0.0004	3.470 [1.748,6.888]
Stroke* *	1 1282	0.0019	3.090 [1.518,6.289]
MI*	0.0803	0.7053	1.084 [0.715,1.643]
MI* *	0.0452	0.8403	1.046 [0.674,1.623]
Target Lesion Revascularization*	0.6107	0.0074	1.842 [1.178,2.879]
Target Lesion Revascularization* *	0.7406	0.0024	2.097 [1.300,3.383]
Any Revascularization*	0.2812	0.0620	1.325 [0.986,1.780]
Any Revascularization* *	0.2528	0.1109	1.288 [0.944,1.757]
All Cause Death + Stroke + MI*	0.2896	0.0688	1.336 [0.978,1.825]
All Cause Death + Stroke + MI* *	0.2550	0.1285	1.290 [0.929,1.793]
All Cause Death + Stroke + MI + Any Revascularization*	0.2355	0.0422	1.266 [1.008,1.589]
All Cause Death + Stroke + MI + Any Revascularization* *	0.1987	0.1029	1.220 [0.961,1.549]
Definite or Probable Stent Thrombosis*	-0.1170	0.8016	0.890 [0.357,2.216]
Definite or Probable Stent Thrombosis* *	-0.3195	0.5124	0.727 [0.279,1.889]

Note: * Cox regression result without adjustment

** Cox regression result with multivariate adjustment

Conclusion

Among this large series of consecutives patients undergoing LM PCI, DM was not associated with an increase in death or ST, but was independently predictive of stroke, and TLR at 6-year follow-up.



Subgroup Bifurcation vs. Non-Bifurcation One-Stent vs. Two-Stent



LM Bifurcation and PCI Strategy





Long-Term Clinical Outcomes (Mean Follow-up of 4.4 Years)



China Interventional Therapeutics in Partnership with TCT

Long-Term Clinical Outcomes (1- vs. 2-Stent) (Mean Follow-up of 4.4 Years)



China International Thermostics in Partmentin with

Validation and Comparison of the Long-Term Prognostic Capability of the SYNTAX Score-II Among 1,528 Consecutives Patients Who Underwent Left Main PCI

Submitted to JACC



Background

- Recently, the SYNTAX Score II (SS-II) was developed in an attempt to individualize and help the decision-making process between PCI and CABG.
- However, there is a paucity of data regarding the utility of SS-II in patients undergoing LM-PCI.
- We sought to evaluate, confirm, and compare the long-term prognostic capacity of the SYNTAX score-II (SS-II) and other risk scores among patients undergoing left main percutaneous coronary intervention (LM-PCI).





Personalizing Risk Assessment for PCI or CABG The SYNTAX Score 2 (From the SYNTAX trial)

Rationale: Low, intermediate, and high categories of anatomical complexity in the SYNTAX score hide lower risk patients in the higher SYNTAX score groups, and viceversa

Strength: Enables direct, personalized comparisons of long-term estimates of mortality for individual patients with LM or 3VD disease referred to PCI or CABG

Online version under development



Ferrarotto Hospital University of Catania

Farooq V, et al. Lancet 2013;381:639–50 C/O Davide Capodanno

Patient Flow



and 1 to 8 years annually



Baseline Clinical Characteristics-1

	Low Tertile	Intermediate Tertile	High Tertile	
	SS-II ≤21	SS-II >21 and ≤28	SS-II >28	p Value
	(n=508)	(n=480)	(n=540)	
Age (years)	50.3±7.3	60.3±7.8	68.8±7.3	<0.0001
Female	22/508 (4.3)	108/480 (22.5)	194/540 (35.9)	<0.0001
Weight (kg)	76.6±9.8	72.4 ± 10.0	67.9±9.9	<0.0001
Height (cm)	170.5±5.8	167.5±6.8	164.8±8.0	<0.0001
Diabetes mellitus	115/508 (22.6)	118/480 (24.6)	136/540 (25.2)	0.60
Hypertension	237/508 (46.7)	272/480 (56.7)	315/540 (58.3)	0.0003
Hyperlipidemia	276/508 (54.3)	236/480 (49.2)	254/540 (47.0)	0.05
Family history of CAD	77/508 (15.2)	51/480 (10.6)	55/540 (10.2)	0.03
Prior myocardial infarction	110/508 (21.7)	115/480 (24.0)	162/540 (30.0)	0.006
Prior PCI	115/508 (22.6)	106/480 (22.1)	122/540 (22.6)	0.97
Prior stroke	18/508 (3.5)	33/480 (6.9)	49/540 (9.1)	0.0009
Peripheral vascular disease	0/508 (0.0)	5/480 (1.0)	75/540 (13.9)	<0.0001
COPD	2/508 (0.4)	3/480 (0.6)	7/540 (1.3)	0.23
LVEF (%)	63.6±6.3	63.2±7.0	61.7±8.9	<0.0001
Creatinine clearance (mL/min)	110.3±24.3	94.1±26.0	68.4±19.1	<0.0001

Baseline Clinical Characteristics-2

	Low Tertile SS-II ≤21 (n=508)	Intermediate Tertile SS-II >21 and ≤28 (n=480)	High Tertile SS-II >28 (n=540)	p Value
Angiographic findings				<0.0001
Isolated LM	67/508 (13.2)	22/480 (4.6)	21/540 (3.9)	
LM + 1 vessel	154/508 (30.3)	97/480 (20.2)	63/540 (11.7)	
LM + 2 vessels	173/508 (34.1)	172/480 (35.8)	215/540 (39.8)	
LM + 3 vessels	114/508 (22.4)	189/480 (39.4)	241/540 (44.6)	
LM lesion location				0.004
Ostium	66/508 (13.0)	51/480 (10.6)	58/540 (10.7)	
Shaft	50/508 (9.8)	24/480 (5.0)	26/540 (4.8)	
Distal bifurcation	392/508 (77.2)	405/480 (84.4)	456/540 (84.4)	
LM with final kissing	198/392 (50.5)	203/405 (50.1)	208/456 (45.6)	0.28
LM bifurcation with 2-stent	128/392 (32.7)	137/405 (33.8)	148/456 (32.5)	0.87

All Cause Mortality



China Interventional Therapeutics in Partnership with To

Cardiac Mortality



Myocardial Infarction



China Interventional Therapeutics in Partnership with TCT

Ischemic-Driven TVR



China Interventional Therapeutics in Partnership with TCT

Death/Stroke/MI



China Interventional Therapeutics in Partnership with TO

Death/Stroke/MI/Revasc.



China Interventional Therapeutics in Partnership with TCT

Independent Predictors of Mortality n=1,528 LM-PCI

Variable	Adjusted HR [95% CI]	P value
Age (per 10 years increase)	1.30 [0.92, 1.83]	0.14
Male gender	1.79 [0.92, 3.49]	0.08
LVEF (per 10% increase)	0.65 [0.49, 0.86]	0.003
COPD	3.28 [1.00, 10.75]	0.05
Creatinine clearance (per 10 cc increase)	1.06 [0.95, 1.17]	0.32
Prior MI	1.69 [1.03, 2.78]	0.04
History of Stroke	1.60 [0.82, 3.15]	0.17
SS II for PCI (per 10 points increase)	1.76 [1.10, 2.82]	0.02

Every Year



Discrimination and Calibration of SYNTAX and Derived Scores for All-Cause Mortality



All Cause Death



Reclassification of Adverse Ischemic Events SYNTAX Score-II vs. Anatomical SYNTAX Score

	NRI or IDI	p Value
All-cause mortality		
NRI	0.25	0.002
IDI	0.015	0.003
Cardiac mortality		
NRI	0.05	0.60
IDI	0.001	0.83
Non-Cardiac mortality		
NRI	0.50	0.0003
IDI	0.007	0.002
Definite/probable stent thrombosis		
NRI	0.06	0.69
IDI	-0.005	0.11
All-cause mortality/stroke/MI		
NRI	0.09	0.15
IDI	0.018	<0.0001
All-cause mortality/stroke/Ml/ischemia		
driven revascularization		
NRI	0.02	0.66
IDI	0.00	0.96

Summary

 Results from this large contemporary cohort of 1,528 consecutives patients undergoing LM-PCI demonstrated favorable short- and long-term outcomes, with low rate of stent thrombosis, revascularization and death.

2) Diabetic patients undergoing LM-PCI had a significant higher rates of stroke (mainly late after PCI) and revascularization after PCI.



Summary

 PCI of LM-bifurcation were frequent among our cohort and showed similar favorable results compared to non bifurcation-LM lesions (isolated ostial or mid shaft)

 The use of a 2 stents strategy for LM-PCI in our cohort appeared safe and associated with low rate of adverse events



Summary

5) Results from this larges series of consecutive patients who underwent LM PCI validated the prognostic capability of the SS-II for long-term mortality among patients with complex coronary artery disease, and confirmed its incremental value in risk prognostication compared to the baseline anatomical SS.

